nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—Fluid overload—Carboplatin—bone cancer	0.0363	0.0527	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Cisplatin—bone cancer	0.0114	0.0165	CcSEcCtD
Dexmedetomidine—Septic shock—Epirubicin—bone cancer	0.0113	0.0164	CcSEcCtD
Dexmedetomidine—Generalised oedema—Cisplatin—bone cancer	0.0111	0.0162	CcSEcCtD
Dexmedetomidine—Fluid overload—Cisplatin—bone cancer	0.0106	0.0155	CcSEcCtD
Dexmedetomidine—Septic shock—Doxorubicin—bone cancer	0.0104	0.0151	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Epirubicin—bone cancer	0.00844	0.0123	CcSEcCtD
Dexmedetomidine—Infection—Carboplatin—bone cancer	0.008	0.0116	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Doxorubicin—bone cancer	0.00781	0.0113	CcSEcCtD
Dexmedetomidine—Nephropathy—Methotrexate—bone cancer	0.00763	0.0111	CcSEcCtD
Dexmedetomidine—Pain—Carboplatin—bone cancer	0.00689	0.01	CcSEcCtD
Dexmedetomidine—Pneumothorax—Epirubicin—bone cancer	0.00683	0.00993	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Cisplatin—bone cancer	0.0065	0.00945	CcSEcCtD
Dexmedetomidine—Hypernatraemia—Epirubicin—bone cancer	0.00647	0.00939	CcSEcCtD
Dexmedetomidine—Wheezing—Cisplatin—bone cancer	0.00643	0.00934	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carboplatin—bone cancer	0.00637	0.00925	CcSEcCtD
Dexmedetomidine—Pneumothorax—Doxorubicin—bone cancer	0.00632	0.00918	CcSEcCtD
Dexmedetomidine—Fluid retention—Cisplatin—bone cancer	0.00628	0.00913	CcSEcCtD
Dexmedetomidine—Body temperature decreased—Epirubicin—bone cancer	0.00606	0.00881	CcSEcCtD
Dexmedetomidine—Hypothermia—Epirubicin—bone cancer	0.00606	0.00881	CcSEcCtD
Dexmedetomidine—Hypernatraemia—Doxorubicin—bone cancer	0.00598	0.00869	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Epirubicin—bone cancer	0.00585	0.0085	CcSEcCtD
Dexmedetomidine—Hypoxia—Methotrexate—bone cancer	0.00572	0.00831	CcSEcCtD
Dexmedetomidine—Generalised oedema—Epirubicin—bone cancer	0.00572	0.0083	CcSEcCtD
Dexmedetomidine—Body temperature decreased—Doxorubicin—bone cancer	0.00561	0.00815	CcSEcCtD
Dexmedetomidine—Hypothermia—Doxorubicin—bone cancer	0.00561	0.00815	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Doxorubicin—bone cancer	0.00541	0.00786	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Epirubicin—bone cancer	0.00535	0.00777	CcSEcCtD
Dexmedetomidine—Generalised oedema—Doxorubicin—bone cancer	0.00529	0.00768	CcSEcCtD
Dexmedetomidine—Renal failure acute—Cisplatin—bone cancer	0.00521	0.00756	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Doxorubicin—bone cancer	0.00495	0.00719	CcSEcCtD
Dexmedetomidine—Neuralgia—Epirubicin—bone cancer	0.00489	0.00711	CcSEcCtD
Dexmedetomidine—Pleural effusion—Methotrexate—bone cancer	0.00474	0.00689	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Epirubicin—bone cancer	0.00459	0.00667	CcSEcCtD
Dexmedetomidine—Neuritis—Epirubicin—bone cancer	0.00455	0.00661	CcSEcCtD
Dexmedetomidine—Neuralgia—Doxorubicin—bone cancer	0.00453	0.00658	CcSEcCtD
Dexmedetomidine—Pleural effusion—Epirubicin—bone cancer	0.00444	0.00645	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Cisplatin—bone cancer	0.00437	0.00635	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00433	0.00629	CcSEcCtD
Dexmedetomidine—Apnoea—Methotrexate—bone cancer	0.00429	0.00623	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Doxorubicin—bone cancer	0.00425	0.00617	CcSEcCtD
Dexmedetomidine—Speech disorder—Methotrexate—bone cancer	0.00422	0.00614	CcSEcCtD
Dexmedetomidine—Neuritis—Doxorubicin—bone cancer	0.00421	0.00612	CcSEcCtD
Dexmedetomidine—Rigors—Epirubicin—bone cancer	0.00416	0.00605	CcSEcCtD
Dexmedetomidine—Pleural effusion—Doxorubicin—bone cancer	0.00411	0.00597	CcSEcCtD
Dexmedetomidine—Sweating increased—Cisplatin—bone cancer	0.00405	0.00588	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00399	0.0058	CcSEcCtD
Dexmedetomidine—Delirium—Epirubicin—bone cancer	0.00395	0.00574	CcSEcCtD
Dexmedetomidine—Oliguria—Methotrexate—bone cancer	0.00394	0.00573	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Epirubicin—bone cancer	0.00387	0.00562	CcSEcCtD
Dexmedetomidine—Rigors—Doxorubicin—bone cancer	0.00385	0.0056	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Epirubicin—bone cancer	0.00374	0.00543	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Epirubicin—bone cancer	0.00371	0.00539	CcSEcCtD
Dexmedetomidine—Respiratory failure—Methotrexate—bone cancer	0.0037	0.00537	CcSEcCtD
Dexmedetomidine—Oliguria—Epirubicin—bone cancer	0.00369	0.00536	CcSEcCtD
Dexmedetomidine—Delirium—Doxorubicin—bone cancer	0.00366	0.00531	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Cisplatin—bone cancer	0.00365	0.0053	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Cisplatin—bone cancer	0.00363	0.00527	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Cisplatin—bone cancer	0.00363	0.00527	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Doxorubicin—bone cancer	0.00358	0.0052	CcSEcCtD
Dexmedetomidine—Atrioventricular block—Epirubicin—bone cancer	0.0035	0.00509	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.00346	0.00502	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Doxorubicin—bone cancer	0.00344	0.00499	CcSEcCtD
Dexmedetomidine—Oliguria—Doxorubicin—bone cancer	0.00341	0.00496	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Epirubicin—bone cancer	0.0034	0.00494	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Epirubicin—bone cancer	0.0034	0.00494	CcSEcCtD
Dexmedetomidine—Bradycardia—Cisplatin—bone cancer	0.00338	0.00492	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Epirubicin—bone cancer	0.00334	0.00485	CcSEcCtD
Dexmedetomidine—Atrioventricular block—Doxorubicin—bone cancer	0.00324	0.00471	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Methotrexate—bone cancer	0.00323	0.0047	CcSEcCtD
Dexmedetomidine—Fluid retention—Epirubicin—bone cancer	0.00323	0.00469	CcSEcCtD
Dexmedetomidine—Blood urea increased—Epirubicin—bone cancer	0.00321	0.00466	CcSEcCtD
Dexmedetomidine—Visual impairment—Cisplatin—bone cancer	0.0032	0.00465	CcSEcCtD
Dexmedetomidine—Sepsis—Methotrexate—bone cancer	0.00315	0.00458	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Doxorubicin—bone cancer	0.00315	0.00457	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.00315	0.00457	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Doxorubicin—bone cancer	0.00309	0.00449	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Cisplatin—bone cancer	0.00309	0.00448	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Epirubicin—bone cancer	0.00303	0.0044	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Cisplatin—bone cancer	0.003	0.00435	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—bone cancer	0.00299	0.00434	CcSEcCtD
Dexmedetomidine—Arrhythmia—Cisplatin—bone cancer	0.00297	0.00431	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—bone cancer	0.00297	0.00431	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—bone cancer	0.00296	0.00431	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—bone cancer	0.00295	0.00429	CcSEcCtD
Dexmedetomidine—Malnutrition—Cisplatin—bone cancer	0.00289	0.0042	CcSEcCtD
Dexmedetomidine—Renal failure acute—Methotrexate—bone cancer	0.00286	0.00415	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.00284	0.00412	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—bone cancer	0.00282	0.0041	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—bone cancer	0.0028	0.00407	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—bone cancer	0.00274	0.00399	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—bone cancer	0.00273	0.00397	CcSEcCtD
Dexmedetomidine—Anaemia—Cisplatin—bone cancer	0.00267	0.00389	CcSEcCtD
Dexmedetomidine—Renal failure acute—Epirubicin—bone cancer	0.00267	0.00388	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.00263	0.00381	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—bone cancer	0.00261	0.0038	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—bone cancer	0.00253	0.00367	CcSEcCtD
Dexmedetomidine—Convulsion—Cisplatin—bone cancer	0.00251	0.00364	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—bone cancer	0.00247	0.00359	CcSEcCtD
Dexmedetomidine—Anxiety—Cisplatin—bone cancer	0.00246	0.00357	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—bone cancer	0.00235	0.00341	CcSEcCtD
Dexmedetomidine—Infection—Cisplatin—bone cancer	0.00235	0.00341	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—bone cancer	0.00234	0.0034	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Cisplatin—bone cancer	0.00231	0.00336	CcSEcCtD
Dexmedetomidine—Tachycardia—Cisplatin—bone cancer	0.00231	0.00335	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Cisplatin—bone cancer	0.00228	0.00332	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—bone cancer	0.00225	0.00326	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.00222	0.00323	CcSEcCtD
Dexmedetomidine—Hypotension—Cisplatin—bone cancer	0.00221	0.00321	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00218	0.00316	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—bone cancer	0.00217	0.00315	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—bone cancer	0.00215	0.00312	CcSEcCtD
Dexmedetomidine—Dyspnoea—Cisplatin—bone cancer	0.00211	0.00306	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—bone cancer	0.00208	0.00302	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.00206	0.00299	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—bone cancer	0.00204	0.00297	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00204	0.00296	CcSEcCtD
Dexmedetomidine—Pain—Cisplatin—bone cancer	0.00202	0.00293	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00201	0.00293	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—bone cancer	0.00199	0.00289	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Cisplatin—bone cancer	0.00195	0.00283	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—bone cancer	0.00192	0.00279	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—bone cancer	0.00191	0.00278	CcSEcCtD
Dexmedetomidine—Body temperature increased—Cisplatin—bone cancer	0.00187	0.00271	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—bone cancer	0.00186	0.00271	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—bone cancer	0.00185	0.00269	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—bone cancer	0.00183	0.00266	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—bone cancer	0.00182	0.00265	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—bone cancer	0.00178	0.00259	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—bone cancer	0.00177	0.00257	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—bone cancer	0.00176	0.00255	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—bone cancer	0.00174	0.00252	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—bone cancer	0.00172	0.00251	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—bone cancer	0.00172	0.00249	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—bone cancer	0.00171	0.00248	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—bone cancer	0.00171	0.00248	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—bone cancer	0.00169	0.00246	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—bone cancer	0.00168	0.00244	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—bone cancer	0.00166	0.0024	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—bone cancer	0.00165	0.00239	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—bone cancer	0.00164	0.00239	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—bone cancer	0.00164	0.00238	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cisplatin—bone cancer	0.00162	0.00235	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—bone cancer	0.00161	0.00234	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—bone cancer	0.0016	0.00232	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—bone cancer	0.00159	0.00231	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—bone cancer	0.00159	0.00231	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—bone cancer	0.00158	0.0023	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—bone cancer	0.00158	0.00229	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—bone cancer	0.00156	0.00226	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—bone cancer	0.00155	0.00225	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—bone cancer	0.00154	0.00224	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—bone cancer	0.00153	0.00223	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—bone cancer	0.00153	0.00222	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—bone cancer	0.00152	0.00221	CcSEcCtD
Dexmedetomidine—Vomiting—Cisplatin—bone cancer	0.0015	0.00218	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—bone cancer	0.0015	0.00217	CcSEcCtD
Dexmedetomidine—Rash—Cisplatin—bone cancer	0.00149	0.00216	CcSEcCtD
Dexmedetomidine—Dermatitis—Cisplatin—bone cancer	0.00149	0.00216	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—bone cancer	0.00149	0.00216	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—bone cancer	0.00147	0.00213	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—bone cancer	0.00147	0.00213	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—bone cancer	0.00143	0.00208	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—bone cancer	0.00142	0.00207	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—bone cancer	0.00142	0.00206	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—bone cancer	0.00141	0.00205	CcSEcCtD
Dexmedetomidine—Nausea—Cisplatin—bone cancer	0.0014	0.00204	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—bone cancer	0.00138	0.00201	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—bone cancer	0.00138	0.002	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—bone cancer	0.00138	0.002	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—bone cancer	0.00137	0.002	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—bone cancer	0.00137	0.00198	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—bone cancer	0.00131	0.0019	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—bone cancer	0.00129	0.00187	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—bone cancer	0.00129	0.00187	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—bone cancer	0.00128	0.00186	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—bone cancer	0.00127	0.00185	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—bone cancer	0.00127	0.00184	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—bone cancer	0.00126	0.00184	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—bone cancer	0.00126	0.00183	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—bone cancer	0.00125	0.00182	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—bone cancer	0.00124	0.0018	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—bone cancer	0.00122	0.00178	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—bone cancer	0.00121	0.00176	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—bone cancer	0.0012	0.00175	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—bone cancer	0.00119	0.00173	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—bone cancer	0.00119	0.00173	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—bone cancer	0.00119	0.00172	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—bone cancer	0.00118	0.00172	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—bone cancer	0.00117	0.0017	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—bone cancer	0.00117	0.00169	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—bone cancer	0.00116	0.00168	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—bone cancer	0.00115	0.00167	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—bone cancer	0.00114	0.00166	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—bone cancer	0.00113	0.00165	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—bone cancer	0.00113	0.00164	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00112	0.00163	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—bone cancer	0.00111	0.00162	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—bone cancer	0.00111	0.00161	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—bone cancer	0.0011	0.0016	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—bone cancer	0.0011	0.00159	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—bone cancer	0.00108	0.00158	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—bone cancer	0.00108	0.00157	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—bone cancer	0.00108	0.00157	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—bone cancer	0.00107	0.00155	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—bone cancer	0.00106	0.00154	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—bone cancer	0.00105	0.00152	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00105	0.00152	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—bone cancer	0.00104	0.00151	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—bone cancer	0.00104	0.00151	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—bone cancer	0.00102	0.00149	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—bone cancer	0.00102	0.00149	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—bone cancer	0.001	0.00145	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—bone cancer	0.001	0.00145	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—bone cancer	0.000998	0.00145	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—bone cancer	0.000992	0.00144	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000969	0.00141	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—bone cancer	0.00096	0.00139	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—bone cancer	0.00096	0.00139	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—bone cancer	0.000959	0.00139	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—bone cancer	0.000959	0.00139	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—bone cancer	0.000925	0.00134	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000918	0.00133	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—bone cancer	0.000887	0.00129	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—bone cancer	0.000887	0.00129	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—bone cancer	0.000887	0.00129	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—bone cancer	0.000857	0.00124	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—bone cancer	0.00083	0.00121	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—bone cancer	0.000824	0.0012	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—bone cancer	0.000817	0.00119	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—bone cancer	0.000816	0.00119	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—bone cancer	0.000812	0.00118	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—bone cancer	0.000802	0.00117	CcSEcCtD
Dexmedetomidine—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000795	0.00255	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000777	0.00249	CbGpPWpGaD
Dexmedetomidine—Vomiting—Epirubicin—bone cancer	0.000771	0.00112	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—bone cancer	0.00077	0.00112	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—bone cancer	0.000768	0.00112	CcSEcCtD
Dexmedetomidine—ADRA2C—GPCR ligand binding—GRM1—bone cancer	0.000767	0.00246	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000766	0.00246	CbGpPWpGaD
Dexmedetomidine—Rash—Epirubicin—bone cancer	0.000765	0.00111	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—bone cancer	0.000764	0.00111	CcSEcCtD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000761	0.00244	CbGpPWpGaD
Dexmedetomidine—Headache—Epirubicin—bone cancer	0.00076	0.0011	CcSEcCtD
Dexmedetomidine—ADRA1B—GPCR ligand binding—GRM1—bone cancer	0.000754	0.00242	CbGpPWpGaD
Dexmedetomidine—Dizziness—Doxorubicin—bone cancer	0.000742	0.00108	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—bone cancer	0.00072	0.00105	CcSEcCtD
Dexmedetomidine—ADRA2A—GPCR ligand binding—GRM4—bone cancer	0.000718	0.0023	CbGpPWpGaD
Dexmedetomidine—Vomiting—Doxorubicin—bone cancer	0.000714	0.00104	CcSEcCtD
Dexmedetomidine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000708	0.00227	CbGpPWpGaD
Dexmedetomidine—Rash—Doxorubicin—bone cancer	0.000708	0.00103	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—bone cancer	0.000707	0.00103	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—bone cancer	0.000703	0.00102	CcSEcCtD
Dexmedetomidine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000698	0.00224	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000696	0.00223	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000668	0.00214	CbGpPWpGaD
Dexmedetomidine—Nausea—Doxorubicin—bone cancer	0.000667	0.000968	CcSEcCtD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000659	0.00212	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000659	0.00211	CbGpPWpGaD
Dexmedetomidine—ADRA1B—LPA receptor mediated events—EGFR—bone cancer	0.000647	0.00208	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR ligand binding—SMO—bone cancer	0.00064	0.00206	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000631	0.00203	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—GRM1—bone cancer	0.000623	0.002	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000622	0.002	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000606	0.00194	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000602	0.00193	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000602	0.00193	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000597	0.00192	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—GRM4—bone cancer	0.000593	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—RGS1—bone cancer	0.000593	0.0019	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR ligand binding—SMO—bone cancer	0.000578	0.00186	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000571	0.00183	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NDUFA12—bone cancer	0.000569	0.00183	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000563	0.00181	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000562	0.0018	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000542	0.00174	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR ligand binding—SMO—bone cancer	0.00054	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—GRM4—bone cancer	0.000538	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—RGS1—bone cancer	0.000538	0.00173	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—GRM4—bone cancer	0.000535	0.00172	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—RGS1—bone cancer	0.000535	0.00172	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR ligand binding—SMO—bone cancer	0.000532	0.00171	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—SPARC—bone cancer	0.000517	0.00166	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—GRM1—bone cancer	0.000514	0.00165	CbGpPWpGaD
Dexmedetomidine—ADRA1B—AMPK Signaling—TP53—bone cancer	0.000512	0.00164	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000507	0.00163	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000503	0.00161	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—GRM4—bone cancer	0.0005	0.0016	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—RGS1—bone cancer	0.0005	0.0016	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000496	0.00159	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—GRM4—bone cancer	0.000492	0.00158	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—RGS1—bone cancer	0.000492	0.00158	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000489	0.00157	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—GRM4—bone cancer	0.000486	0.00156	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—RGS1—bone cancer	0.000486	0.00156	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—SPARC—bone cancer	0.000483	0.00155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—GNA11—bone cancer	0.000473	0.00152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NT5C3A—bone cancer	0.000472	0.00151	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—GRM1—bone cancer	0.000467	0.0015	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—GRM1—bone cancer	0.000464	0.00149	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NDUFA12—bone cancer	0.000462	0.00148	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—GRM4—bone cancer	0.000454	0.00146	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—RGS1—bone cancer	0.000454	0.00146	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—GRM4—bone cancer	0.000447	0.00143	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—RGS1—bone cancer	0.000447	0.00143	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—GNA11—bone cancer	0.000442	0.00142	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR ligand binding—SMO—bone cancer	0.000439	0.00141	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—GRM1—bone cancer	0.000433	0.00139	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.00043	0.00138	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IL3—bone cancer	0.000429	0.00138	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—GRM1—bone cancer	0.000426	0.00137	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000426	0.00137	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NDUFA12—bone cancer	0.000425	0.00136	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000424	0.00136	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—GRM1—bone cancer	0.000421	0.00135	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.00042	0.00135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—RGS1—bone cancer	0.000406	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—GRM4—bone cancer	0.000406	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IL3—bone cancer	0.0004	0.00129	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NDUFA12—bone cancer	0.0004	0.00128	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—GRM1—bone cancer	0.000393	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SPARC—bone cancer	0.000392	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—GRM1—bone cancer	0.000387	0.00124	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000384	0.00123	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000384	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NT5C3A—bone cancer	0.000383	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—GRM4—bone cancer	0.000369	0.00118	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—RGS1—bone cancer	0.000369	0.00118	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000364	0.00117	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000359	0.00115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—GNA11—bone cancer	0.000359	0.00115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—GRM1—bone cancer	0.000352	0.00113	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NT5C3A—bone cancer	0.000352	0.00113	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NT5C3A—bone cancer	0.000332	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—GNA11—bone cancer	0.000331	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—SMO—bone cancer	0.000329	0.00105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IL3—bone cancer	0.000325	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—GRM1—bone cancer	0.00032	0.00103	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GRM4—bone cancer	0.000318	0.00102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RGS1—bone cancer	0.000318	0.00102	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000301	0.000967	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—GNA11—bone cancer	0.000301	0.000965	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—IL3—bone cancer	0.0003	0.000963	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—GNA11—bone cancer	0.000299	0.000959	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—SMO—bone cancer	0.000297	0.000952	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000296	0.000949	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GRM4—bone cancer	0.000287	0.000921	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RGS1—bone cancer	0.000287	0.000921	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—PLAU—bone cancer	0.000281	0.000903	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—GNA11—bone cancer	0.000279	0.000896	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—SMO—bone cancer	0.000277	0.00089	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GRM1—bone cancer	0.000276	0.000884	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—GNA11—bone cancer	0.000275	0.000882	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—SMO—bone cancer	0.000273	0.000876	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL3—bone cancer	0.000273	0.000875	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—GNA11—bone cancer	0.000271	0.000871	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL3—bone cancer	0.000271	0.00087	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GRM4—bone cancer	0.000268	0.00086	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RGS1—bone cancer	0.000268	0.00086	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GRM4—bone cancer	0.000264	0.000847	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RGS1—bone cancer	0.000264	0.000847	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PLAU—bone cancer	0.000263	0.000843	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000255	0.000819	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—GNA11—bone cancer	0.000254	0.000814	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL3—bone cancer	0.000253	0.000812	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NT5C3A—bone cancer	0.00025	0.000801	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—GNA11—bone cancer	0.00025	0.000801	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL3—bone cancer	0.000249	0.000799	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GRM1—bone cancer	0.000249	0.000799	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL3—bone cancer	0.000246	0.00079	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000246	0.000788	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GRM1—bone cancer	0.000232	0.000746	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL3—bone cancer	0.00023	0.000738	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GRM1—bone cancer	0.000229	0.000734	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	0.000227	0.000728	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL3—bone cancer	0.000226	0.000726	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—SMO—bone cancer	0.000225	0.000723	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RGS1—bone cancer	0.000218	0.000699	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GRM4—bone cancer	0.000218	0.000699	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PLAU—bone cancer	0.000213	0.000685	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000211	0.000679	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ENO2—bone cancer	0.000207	0.000663	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—GNA11—bone cancer	0.000206	0.000661	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL3—bone cancer	0.000206	0.00066	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SMO—bone cancer	0.000194	0.000623	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—DHFR—bone cancer	0.000192	0.000615	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GRM1—bone cancer	0.000189	0.000606	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL3—bone cancer	0.000187	0.000599	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GNA11—bone cancer	0.000179	0.000575	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GNA11—bone cancer	0.000178	0.00057	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SMO—bone cancer	0.000175	0.000563	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ENO2—bone cancer	0.000168	0.000538	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ATF1—bone cancer	0.000165	0.00053	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SMO—bone cancer	0.000164	0.000526	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP3A4—bone cancer	0.000162	0.000521	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SMO—bone cancer	0.000161	0.000517	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL3—bone cancer	0.000161	0.000517	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GNA11—bone cancer	0.00016	0.000515	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—DHFR—bone cancer	0.000156	0.0005	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ENO2—bone cancer	0.000154	0.000494	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GNA11—bone cancer	0.00015	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ATF1—bone cancer	0.000149	0.000478	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GNA11—bone cancer	0.000147	0.000473	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GNA11—bone cancer	0.000145	0.000467	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL3—bone cancer	0.000145	0.000466	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ENO2—bone cancer	0.000145	0.000466	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—DHFR—bone cancer	0.000143	0.000459	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ATF1—bone cancer	0.000139	0.000447	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTP1—bone cancer	0.000139	0.000446	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFBR2—bone cancer	0.000138	0.000442	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ATF1—bone cancer	0.000137	0.00044	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL3—bone cancer	0.000136	0.000436	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—DHFR—bone cancer	0.000135	0.000432	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL3—bone cancer	0.000134	0.000429	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GNA11—bone cancer	0.000134	0.000429	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SMO—bone cancer	0.000133	0.000427	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP3A4—bone cancer	0.000132	0.000423	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1R—bone cancer	0.00013	0.000416	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GNA11—bone cancer	0.000126	0.000404	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	0.000124	0.000399	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GNA11—bone cancer	0.000122	0.00039	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP3A4—bone cancer	0.000121	0.000389	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1R—bone cancer	0.000117	0.000375	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	0.000116	0.000373	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	0.000114	0.000367	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP3A4—bone cancer	0.000114	0.000366	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000114	0.000365	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ATF1—bone cancer	0.000113	0.000363	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—bone cancer	0.000113	0.000363	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTP1—bone cancer	0.000113	0.000362	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL3—bone cancer	0.00011	0.000354	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ENO2—bone cancer	0.000109	0.000351	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1R—bone cancer	0.000109	0.000351	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1R—bone cancer	0.000108	0.000345	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—bone cancer	0.000106	0.000339	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTP1—bone cancer	0.000104	0.000332	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—DHFR—bone cancer	0.000101	0.000326	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTP1—bone cancer	9.77e-05	0.000313	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GNA11—bone cancer	9.48e-05	0.000304	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	9.43e-05	0.000303	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KIT—bone cancer	9.4e-05	0.000302	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ENO2—bone cancer	9.26e-05	0.000297	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1R—bone cancer	8.87e-05	0.000285	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—BRAF—bone cancer	8.83e-05	0.000283	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP3A4—bone cancer	8.59e-05	0.000276	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—DHFR—bone cancer	8.59e-05	0.000276	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—bone cancer	8.58e-05	0.000275	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—bone cancer	8.56e-05	0.000275	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KIT—bone cancer	8.48e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GNA11—bone cancer	8.03e-05	0.000258	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BRAF—bone cancer	7.97e-05	0.000256	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KIT—bone cancer	7.92e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KIT—bone cancer	7.8e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—bone cancer	7.73e-05	0.000248	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BRAF—bone cancer	7.45e-05	0.000239	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MDM2—bone cancer	7.4e-05	0.000237	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—bone cancer	7.35e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BRAF—bone cancer	7.33e-05	0.000235	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP3A4—bone cancer	7.28e-05	0.000234	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.24e-05	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—bone cancer	7.22e-05	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—bone cancer	7.19e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—bone cancer	7.1e-05	0.000228	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—bone cancer	6.68e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—bone cancer	6.44e-05	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—bone cancer	6.43e-05	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—bone cancer	6.26e-05	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—bone cancer	6.24e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—bone cancer	6.23e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—bone cancer	6.14e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—bone cancer	6.05e-05	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—bone cancer	5.86e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—bone cancer	5.84e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—bone cancer	5.81e-05	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—bone cancer	5.65e-05	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—bone cancer	5.42e-05	0.000174	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—bone cancer	5.37e-05	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—bone cancer	5.34e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—bone cancer	5.28e-05	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—bone cancer	5.19e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—bone cancer	5.07e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—bone cancer	5.06e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—bone cancer	5.06e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—bone cancer	4.57e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—bone cancer	4.41e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—bone cancer	4.29e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—bone cancer	4.26e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—bone cancer	4.25e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—bone cancer	4.2e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—bone cancer	3.83e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—bone cancer	3.81e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—bone cancer	3.58e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—bone cancer	3.52e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—bone cancer	3.46e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—bone cancer	3.23e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—bone cancer	2.91e-05	9.33e-05	CbGpPWpGaD
